Home > Healthcare > Pharmaceuticals > Finished Drug Form > Immunomodulators Market

Immunomodulators Market Share

Report ID: GMI11706
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Immunomodulators Market Share

The market is highly competitive, featuring a mix of major global players and smaller to medium-sized companies vying for market share. A key aspect of market strategy involves the continuous introduction of innovations, such as chimeric antigen receptor T-cell therapy, JAK inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators. Notably, prominent industry players exert considerable influence in this dynamic landscape, often driving advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers play a crucial role in strengthening market positions and expanding global footprints amidst evolving regulatory environments.

Immunomodulators Market Companies

Some of the eminent market participants operating in the immunomodulators industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Limited
UCB S.A.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The industry was valued at approximately USD 217.7 billion in 2023 and is projected to grow at a 6.7% CAGR from 2024 to 2032.

The immunosuppressants segment led the market with a revenue of USD 136.5 billion in 2023 and is expected to see significant growth due to the increasing demand for organ transplant rejection medications.

The North American market is forecasted to reach USD 178.3 billion by 2032. In 2023, the U.S. dominated the region with a revenue of USD 91.2 billion, driven by the high prevalence of chronic diseases.

Key players include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., and Johnson & Johnson.